Abstract: Compounds represented by Formula (I):
or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.
Type:
Grant
Filed:
August 23, 2002
Date of Patent:
June 1, 2004
Assignee:
Merck Frosst Canada & Co.
Inventors:
Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
Abstract: Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
Abstract: Compounds represented by Formula (I):
or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.
Type:
Grant
Filed:
May 24, 2002
Date of Patent:
January 13, 2004
Assignee:
Merck Frosst Canada & Co.
Inventors:
Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
Abstract: Amino acid di- and tri-peptide analogs having C-terminal vinylic groups, pharmaceutical compositions containing the analogs and methods of treating diseases using cysteinyl protease inhibitors; particularly neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury.
Type:
Grant
Filed:
June 22, 1999
Date of Patent:
September 9, 2003
Inventors:
Benito Munoz, Kuman Srinivasan, Bowei Wang
Abstract: The present invention provides a method of treating a neurodegenerative disease, and in particular Alzheimer's disease, Mild Cognitive Impairment or other objective memory impairment which comprises the co-administration of ARICEPT or other cholinesterase inhibitor or cholenergic angonist and an effective amount of a selective COX-2 inhibitor. Although a wide range of COX-2 inhibitors may be employed in combination with ARICEPT, there are preferred choices which are specifically set forth herein.
Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
Type:
Grant
Filed:
February 28, 2001
Date of Patent:
November 26, 2002
Assignee:
Merck Frosst Canada, Inc.
Inventors:
Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
Abstract: Disclosed herein are compounds of Formula I
and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation.
Type:
Grant
Filed:
January 4, 2000
Date of Patent:
April 16, 2002
Assignee:
Merck & Co., Inc.
Inventors:
Charles G. Caldwell, Malcolm Maccoss, William K. Hagmann, Shrenik K. Shah, Kothandaraman Shankaran, Karla L. Furman
Abstract: Disclosed are novel chromophore containing compounds of Formula I and their use in determining interleukin-1&bgr; convertase (ICE) activity. ICE has been implicated in inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes.
Type:
Grant
Filed:
December 17, 1991
Date of Patent:
February 19, 2002
Assignee:
Merck & Co., Inc.
Inventors:
Kevin T. Chapman, Malcolm Maccoss, Richard A. Mumford, Nancy A. Thornberry, Jeffrey R. Weidner, William K. Hagmann
Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Type:
Grant
Filed:
February 25, 1997
Date of Patent:
December 11, 2001
Assignee:
Merck Frosst Canada & Co.
Inventors:
Petpiboon Prasit, Daniel Guay, Zhaoyin Wang, Serge Leger, Michel Therien
Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Type:
Grant
Filed:
October 21, 1999
Date of Patent:
January 2, 2001
Assignee:
Merck Frosst Canada & Co.
Inventors:
Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
Abstract: This application relates to a method of treating a disease susceptible to treatment with a non-steroidal anti-inflammatory drug by administering to a patient once daily an effective amount of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.
Abstract: Disclosed herein are compounds of Formula I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation.
Type:
Grant
Filed:
September 25, 1996
Date of Patent:
March 28, 2000
Assignee:
Merck & Co., Inc.
Inventors:
Charles G. Caldwell, William K. Hagmann, Malcolm Maccoss, Shrenik K. Shah, Kothandaraman Shankaran, Karla L. Furman
Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
Type:
Grant
Filed:
October 29, 1998
Date of Patent:
December 14, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
Abstract: Substituted 2-aminopyridine compounds of Formula (I) and pharmaceutically acceptable salts which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders.
Type:
Grant
Filed:
May 22, 1997
Date of Patent:
October 26, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Craig Esser, William Hagmann, William Hoffman, Shrenik Shah, Kenny Wong, Renee Chabin, Ravindra Guthikonda, Malcolm Maccoss, Charles Caldwell, Philippe Durette
Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
October 19, 1999
Assignee:
Merck Frosst Canada, Inc.
Inventors:
Daniel Guay, Chun-Sing Li, Nathalie Ouimet
Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
Type:
Grant
Filed:
October 10, 1997
Date of Patent:
October 19, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Stacia Kargman, Jilly Evans, Thomas J. Simon
Abstract: Novel N-carboxyalkylpeptidyl compounds of formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.
Type:
Grant
Filed:
May 1, 1997
Date of Patent:
August 3, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Charles G. Caldwell, Kevin T. Chapman, Craig K. Esser, William K. Hagmann, Ihor E. Kopka, Scott A. Polo, Soumya P. Sahoo, Philippe L. Durette